Pasin Hemachudha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pasin Hemachudha has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Thanakit Pongpitakmetha
Chulalongkorn University
8 shared publications - Thiravat Hemachudha
Faculty of Medicine, Chulalongkorn University, Bangkok Thailand
7 shared publications - Abhinbhen Wasontiwong Saraya
Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
4 shared publications Thiravat Hemachudha
Center of Excellence in Integrative Medicine and Public Health, College of Eastern Medicine , Rangsit University , Pathum Thani , Thailand
4 shared publicationsWanakorn Rattanawong
Comprehensive Headache and Orofacial Pain (CHOP) Research Group , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand
4 shared publications- Wanakorn Rattanawong
Chulalongkorn University
4 shared publications
Latest Publications
- 15 September 2026
- Published by Medical Association of Thailand in Journal of the Medical Association of Thailand
- Vol. 109 (9) , 764
Atypical Presentation of a MERRF-Like Phenotype with Late-Onset Visual Decline and Stimulus-Sensitive Myoclonus: A Case Report
Background: Myoclonic epilepsy with ragged red fibers (MERRF) is a rare mitochondrial encephalomyopathy with highly variable clinical expression. Although the classical phenotype includes myoclonus, generalized seizures, cerebellar ataxia, and ragged red fibers on muscle biopsy, many patients present with incomplete or misleading features. Case Report: This case report describes a late-onset presentation in a 43-year-old woman with a 5-year history of progressive bilateral visual decline initially attributed to cataracts. Persistent visual impairment after lens extraction prompted further evaluation. During ophthalmological examination, she developed reproducible generalized myoclonic jerks triggered by visual stimulation. Fundoscopy revealed retinitis pigmentosa, and further history identified progressive sensorineural hearing loss. Neurological examination showed stimulus-provoked myoclonus and mild proximal weakness with preserved cognition. Electroencephalography demonstrated generalized 3 Hz spike-wave discharges with a photoparoxysmal response, and brain magnetic resonance imaging showed symmetrical basal ganglia hyperintensities. Muscle biopsy revealed scattered cytochrome c oxidase-negative/succinate dehydrogenase-positive fibers, supporting mitochondrial dysfunction. Whole mitochondrial genome sequencing of peripheral blood did not detect pathogenic variants, highlighting the limitations of genetic testing. In the absence of molecular confirmation, these findings are consistent with a mitochondrial encephalomyopathy within the MERRF spectrum. Conclusion: The patient was treated with levetiracetam and a mitochondrial supplement regimen, with clinical stability at 18-month follow-up and no further seizures. This case illustrates how late-onset, atypical presentations—particularly visual symptoms, intermittent myoclonus, and absent family history—may obscure underlying mitochondrial disease. It highlights the importance of integrating multimodal investigations and reinforces the continued relevance of muscle biopsy in the genomic era.
- 15 September 2026
- Published by Medical Association of Thailand in Journal of the Medical Association of Thailand
- Vol. 109 (9) , 764
Atypical Presentation of a MERRF-Like Phenotype with Late-Onset Visual Decline and Stimulus-Sensitive Myoclonus: A Case Report
Background: Myoclonic epilepsy with ragged red fibers (MERRF) is a rare mitochondrial encephalomyopathy with highly variable clinical expression. Although the classical phenotype includes myoclonus, generalized seizures, cerebellar ataxia, and ragged red fibers on muscle biopsy, many patients present with incomplete or misleading features. Case Report: This case report describes a late-onset presentation in a 43-year-old woman with a 5-year history of progressive bilateral visual decline initially attributed to cataracts. Persistent visual impairment after lens extraction prompted further evaluation. During ophthalmological examination, she developed reproducible generalized myoclonic jerks triggered by visual stimulation. Fundoscopy revealed retinitis pigmentosa, and further history identified progressive sensorineural hearing loss. Neurological examination showed stimulus-provoked myoclonus and mild proximal weakness with preserved cognition. Electroencephalography demonstrated generalized 3 Hz spike-wave discharges with a photoparoxysmal response, and brain magnetic resonance imaging showed symmetrical basal ganglia hyperintensities. Muscle biopsy revealed scattered cytochrome c oxidase-negative/succinate dehydrogenase-positive fibers, supporting mitochondrial dysfunction. Whole mitochondrial genome sequencing of peripheral blood did not detect pathogenic variants, highlighting the limitations of genetic testing. In the absence of molecular confirmation, these findings are consistent with a mitochondrial encephalomyopathy within the MERRF spectrum. Conclusion: The patient was treated with levetiracetam and a mitochondrial supplement regimen, with clinical stability at 18-month follow-up and no further seizures. This case illustrates how late-onset, atypical presentations—particularly visual symptoms, intermittent myoclonus, and absent family history—may obscure underlying mitochondrial disease. It highlights the importance of integrating multimodal investigations and reinforces the continued relevance of muscle biopsy in the genomic era.
- 11 August 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218316
Teaching NeuroImage: An Unusual Cause of Deep Cerebral Venous Sinus Thrombosis
- 11 August 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218316
Teaching NeuroImage: An Unusual Cause of Deep Cerebral Venous Sinus Thrombosis
- Open Access
- 1 August 2025
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 19 (4) , 197-209
Understanding the genetics and neurology: an overview of adult neurogenetics
Neurogenetics investigates the genetic basis of neurological disorders. It encompasses conditions ranging from neurodegenerative diseases with predominantly polygenic risk genes, such as Alzheimer's and Parkinson's, to monogenic diseases and repeated expansion disorders within movement and neuromuscular disorders, such as Friedreich ataxia and muscular dystrophies. Significant advances in recent years that have revolutionized our understanding of disease mechanisms and paved the way for personalized medicine approaches are due to the field of neurogenetics, with its intricate relationship both with clinical and genetic research. Therefore, all neurologists, even in resource-limited settings, are aware of the critical genetic basis; standard molecular diagnostic techniques such as next-generation sequencing, whole exome, and whole genome sequencing; and possible therapeutic modalities of their field. This review will also touch on elements of the neurogenetic clinic in tertiary care, ethical considerations, and insight into ongoing research that would help improve patient care and enhance clinical outcomes.
- 1 August 2025
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 19 (4) , 197-209
Open AccessUnderstanding the genetics and neurology: an overview of adult neurogenetics
Neurogenetics investigates the genetic basis of neurological disorders. It encompasses conditions ranging from neurodegenerative diseases with predominantly polygenic risk genes, such as Alzheimer's and Parkinson's, to monogenic diseases and repeated expansion disorders within movement and neuromuscular disorders, such as Friedreich ataxia and muscular dystrophies. Significant advances in recent years that have revolutionized our understanding of disease mechanisms and paved the way for personalized medicine approaches are due to the field of neurogenetics, with its intricate relationship both with clinical and genetic research. Therefore, all neurologists, even in resource-limited settings, are aware of the critical genetic basis; standard molecular diagnostic techniques such as next-generation sequencing, whole exome, and whole genome sequencing; and possible therapeutic modalities of their field. This review will also touch on elements of the neurogenetic clinic in tertiary care, ethical considerations, and insight into ongoing research that would help improve patient care and enhance clinical outcomes.
- Open Access
- 6 March 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-6
Mycobacterium celatum encephalitis in an immunocompromised host mimicking autoimmune striatal encephalitis: the first case report
Encephalitis is rarely caused by nontuberculous mycobacteria (NTM), which is generally not considered a highly virulent pathogen. However, NTM encephalitis in immunocompromised hosts occurs with varied clinical presentations, posing a diagnostic challenge in clinical practice. This study aims to describe an atypical case of NTM encephalitis caused by Mycobacterium celatum, which has not previously been reported to infect the central nervous system of immunocompromised hosts, mimicking autoimmune striatal encephalitis (ASE). A 35-year-old immunosuppressed woman presented with prolonged fever for 4 months and rapidly progressive cognitive decline for 3 months. Neurological examination showed impaired cognition and parkinsonism. Laboratory testing was unremarkable. Her brain imaging on T2-weighted fluid-attenuated inversion recovery (T2/FLAIR) exhibited lesions involving basal ganglia and subcortical white matter in both hemispheres, mimicking ASE. Cerebrospinal fluid (CSF) analysis revealed mild pleocytosis with normal glucose and protein levels. CSF comprehensive microbiological studies and autoimmune panels were negative. ASE was suspected, and immunotherapies were given. Despite immunotherapies, her condition worsened with seizures, warranting a stereotactic brain biopsy to achieve a definite diagnosis. Her brain tissue pathology result was non-specific. However, we identified M. celatum from her brain tissue. Thus, the final diagnosis was M. celatum encephalitis. Therefore, we discontinued immunotherapies and started anti-NTM treatment, including isoniazid, rifampicin, ethambutol, and levofloxacin. After completing a 16-month treatment course, her clinical condition was stable, afebrile, and seizure-free. We proposed that NTM invades the central nervous system and also triggers immune dysregulation, developing features resembling ASE. In case of suspicious autoimmune encephalitis with poor response to immunotherapies, a tissue biopsy should be performed to exclude chronic infection.
- 6 March 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-6
Open AccessMycobacterium celatum encephalitis in an immunocompromised host mimicking autoimmune striatal encephalitis: the first case report
Encephalitis is rarely caused by nontuberculous mycobacteria (NTM), which is generally not considered a highly virulent pathogen. However, NTM encephalitis in immunocompromised hosts occurs with varied clinical presentations, posing a diagnostic challenge in clinical practice. This study aims to describe an atypical case of NTM encephalitis caused by Mycobacterium celatum, which has not previously been reported to infect the central nervous system of immunocompromised hosts, mimicking autoimmune striatal encephalitis (ASE). A 35-year-old immunosuppressed woman presented with prolonged fever for 4 months and rapidly progressive cognitive decline for 3 months. Neurological examination showed impaired cognition and parkinsonism. Laboratory testing was unremarkable. Her brain imaging on T2-weighted fluid-attenuated inversion recovery (T2/FLAIR) exhibited lesions involving basal ganglia and subcortical white matter in both hemispheres, mimicking ASE. Cerebrospinal fluid (CSF) analysis revealed mild pleocytosis with normal glucose and protein levels. CSF comprehensive microbiological studies and autoimmune panels were negative. ASE was suspected, and immunotherapies were given. Despite immunotherapies, her condition worsened with seizures, warranting a stereotactic brain biopsy to achieve a definite diagnosis. Her brain tissue pathology result was non-specific. However, we identified M. celatum from her brain tissue. Thus, the final diagnosis was M. celatum encephalitis. Therefore, we discontinued immunotherapies and started anti-NTM treatment, including isoniazid, rifampicin, ethambutol, and levofloxacin. After completing a 16-month treatment course, her clinical condition was stable, afebrile, and seizure-free. We proposed that NTM invades the central nervous system and also triggers immune dysregulation, developing features resembling ASE. In case of suspicious autoimmune encephalitis with poor response to immunotherapies, a tissue biopsy should be performed to exclude chronic infection.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2) , e090601
Plasma phosphorylated tau 217 in relation to Alzheimer’s prevalence and cognition in Thailand
Background: Biomarkers for Alzheimer's disease (AD) in blood samples has the potential to facilitate early diagnosis and improve the accuracy of AD diagnosis. Plasma phosphorylated tau (p‐tau) is a key biomarker for AD; however, its utility for estimating the prevalence of AD and screening for cognitive impairment is still limited.Method: The study recruited 71 participants over the age of 40. Plasma p‐tau 217 levels and neuropsychological data were measured. AD prevalence was estimated using a pre‐defined cut‐off derived from an independent cohort with biomarker‐defined AD status according to the current framework (Jack et. al., 2018). The correlation between plasma p‐tau 217 levels and neuropsychological data were also evaluated.Result: The median age of participants was 62 years and overall clinical dementia rating of 0. The median Montreal cognitive assessment (MoCA) and Mini‐Mental State Examination (MMSE) score was 26 and 29 consecutively. Plasma p‐tau 217 levels showed a negative correlation with both neurocognitive tests (MoCA, Rho = ‐0.082, P = 0.5; MMSE, Rho = ‐0.26, P = 0.027). The estimated prevalence of AD was 16.9% (95% CI 9.9‐27.3) when using plasma p‐tau 217 as a biomarker, which was lower than the prevalence estimated using amyloid abnormalities of 30.1% (Jansen et. al., 2022).Conclusion: The results of this study suggest the possibility of plasma p‐tau 217 for estimating AD prevalence and cognition. It may represent those at risk of clinical onset. However, further studies are needed to investigate its utility in risk stratification, and cognitive performance assessment.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2) , e090601
Open AccessPlasma phosphorylated tau 217 in relation to Alzheimer’s prevalence and cognition in Thailand
Background: Biomarkers for Alzheimer's disease (AD) in blood samples has the potential to facilitate early diagnosis and improve the accuracy of AD diagnosis. Plasma phosphorylated tau (p‐tau) is a key biomarker for AD; however, its utility for estimating the prevalence of AD and screening for cognitive impairment is still limited.Method: The study recruited 71 participants over the age of 40. Plasma p‐tau 217 levels and neuropsychological data were measured. AD prevalence was estimated using a pre‐defined cut‐off derived from an independent cohort with biomarker‐defined AD status according to the current framework (Jack et. al., 2018). The correlation between plasma p‐tau 217 levels and neuropsychological data were also evaluated.Result: The median age of participants was 62 years and overall clinical dementia rating of 0. The median Montreal cognitive assessment (MoCA) and Mini‐Mental State Examination (MMSE) score was 26 and 29 consecutively. Plasma p‐tau 217 levels showed a negative correlation with both neurocognitive tests (MoCA, Rho = ‐0.082, P = 0.5; MMSE, Rho = ‐0.26, P = 0.027). The estimated prevalence of AD was 16.9% (95% CI 9.9‐27.3) when using plasma p‐tau 217 as a biomarker, which was lower than the prevalence estimated using amyloid abnormalities of 30.1% (Jansen et. al., 2022).Conclusion: The results of this study suggest the possibility of plasma p‐tau 217 for estimating AD prevalence and cognition. It may represent those at risk of clinical onset. However, further studies are needed to investigate its utility in risk stratification, and cognitive performance assessment.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S14)
Plasma phosphorylated tau 181 in relation to Alzheimer’s prevalence and cognition in the Thai community
Background: The identification of biomarkers for Alzheimer’s disease (AD) in blood samples has the potential to facilitate early diagnosis and improve the accuracy of AD diagnosis. Plasma phosphorylated tau (p‐tau) is a promising biomarker for AD; however, its utility in estimating the prevalence of AD and screening for cognitive impairment in non‐demented populations has yet to be explored in Thailand.Method: The study recruited 110 non‐demented participants over the age of 40 from the family members of patients attending a neurology clinic. Plasma p‐tau 181 levels were measured, and AD prevalence was estimated using a pre‐defined cut‐off derived from an independent cohort with biomarker‐defined AD status according to the current framework (Jack et. al., 2018). The correlation between plasma p‐tau 181 levels and. neuropsychological data were also evaluated.Result: The median age of participants was 66 years, and the median mini‐mental state examination score was 29. The estimated prevalence of AD was 20.0% (95% CI 13.6‐28.4) in preclinical and mild cognitive impairment patients when using p‐tau as a biomarker, which was lower than the prevalence estimated using amyloid abnormalities of 30.1% (95% CI 29.2‐31.1)(Jansen et. al., 2022) (X 2 [N = 8944] = 5.28, p = .022). Plasma p‐tau 181 levels also showed a negative correlation with neurocognitive test scores (Rho = ‐0.24, P .013).Conclusion: The results of this study suggest that plasma p‐tau 181 is a promising biomarker for the estimation of AD prevalence in non‐demented populations in Thailand and may represent those at risk of clinical onset. However, further studies are needed to investigate its utility in risk stratification, public health preparedness, and cognitive performance assessment.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S14)
Open AccessPlasma phosphorylated tau 181 in relation to Alzheimer’s prevalence and cognition in the Thai community
Background: The identification of biomarkers for Alzheimer’s disease (AD) in blood samples has the potential to facilitate early diagnosis and improve the accuracy of AD diagnosis. Plasma phosphorylated tau (p‐tau) is a promising biomarker for AD; however, its utility in estimating the prevalence of AD and screening for cognitive impairment in non‐demented populations has yet to be explored in Thailand.Method: The study recruited 110 non‐demented participants over the age of 40 from the family members of patients attending a neurology clinic. Plasma p‐tau 181 levels were measured, and AD prevalence was estimated using a pre‐defined cut‐off derived from an independent cohort with biomarker‐defined AD status according to the current framework (Jack et. al., 2018). The correlation between plasma p‐tau 181 levels and. neuropsychological data were also evaluated.Result: The median age of participants was 66 years, and the median mini‐mental state examination score was 29. The estimated prevalence of AD was 20.0% (95% CI 13.6‐28.4) in preclinical and mild cognitive impairment patients when using p‐tau as a biomarker, which was lower than the prevalence estimated using amyloid abnormalities of 30.1% (95% CI 29.2‐31.1)(Jansen et. al., 2022) (X 2 [N = 8944] = 5.28, p = .022). Plasma p‐tau 181 levels also showed a negative correlation with neurocognitive test scores (Rho = ‐0.24, P .013).Conclusion: The results of this study suggest that plasma p‐tau 181 is a promising biomarker for the estimation of AD prevalence in non‐demented populations in Thailand and may represent those at risk of clinical onset. However, further studies are needed to investigate its utility in risk stratification, public health preparedness, and cognitive performance assessment.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S15)
The generalizability of proposed reference values for plasma neurofilament light chain in cognitively healthy adults in Thailand
Background: Despite being an established biomarker for quantifying neuroaxonal injury in research, the clinical utility of neurofilament light chain (NFL) for assessing individual patients is limited, primarily due to the confounding effect of aging on its levels. Although many studies reported age‐specific cutoff values in neurologically healthy population of European descent in high‐income countries, evidence suggests that the value of neurodegenerative biomarkers may differ in ethnically and socioeconomically underrepresented populations. In this study, we aimed to evaluate the acceptability of the reported NFL cutoff values for local clinical use by examining specimens from healthy Thai cohorts.Method: This study enrolled participants without neurological disorder and normal cognitive examination from two distinct cohorts in Bangkok, Thailand, ranging in age from 40 to 90 years old. Plasma levels of NFL were quantified using the single molecule array. By utilizing reference data from previous studies (Simrén et al., 2022; Bornhorst et al., 2022), the proportion of participants exceeding the proposed cutoff values were estimated and compared to the expected values. Furthermore, the cohort was stratified by age group and methods similar to prior studies were employed to determine age‐specific cutoff values.Result: One hundred and three participants were included, comprising of 69 females (67%), with a median age of 65.4 years (interquartile range (IQR): 56.7, 70.3) and a cognitive z‐score of 0.11 (IQR: ‐0.44, 0.63). Using the reference threshold from prior studies, plasma NFL were elevated in 4 participants (3.9%, 95% confidence interval: 1.0‐9.6%) which is consistent with the expected prevalence of 5% (as 95th percentile cutoffs were used). Subsequently, we determined age‐specific plasma NFL cut‐off values for each decade through quantile regression, values ranging from 7.2 pg/mL for 40‐50 years to 58.2 pg/mL for >80 years.Conclusion: Our initial findings suggest that the previously established cutoffs for plasma NFL may be applicable in Thailand. Nonetheless, further studies with a larger and more diverse sample size may be necessary in order to fully validate the generalizability of these cutoffs and potentially establish more specific thresholds for local use.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S15)
Open AccessThe generalizability of proposed reference values for plasma neurofilament light chain in cognitively healthy adults in Thailand
Background: Despite being an established biomarker for quantifying neuroaxonal injury in research, the clinical utility of neurofilament light chain (NFL) for assessing individual patients is limited, primarily due to the confounding effect of aging on its levels. Although many studies reported age‐specific cutoff values in neurologically healthy population of European descent in high‐income countries, evidence suggests that the value of neurodegenerative biomarkers may differ in ethnically and socioeconomically underrepresented populations. In this study, we aimed to evaluate the acceptability of the reported NFL cutoff values for local clinical use by examining specimens from healthy Thai cohorts.Method: This study enrolled participants without neurological disorder and normal cognitive examination from two distinct cohorts in Bangkok, Thailand, ranging in age from 40 to 90 years old. Plasma levels of NFL were quantified using the single molecule array. By utilizing reference data from previous studies (Simrén et al., 2022; Bornhorst et al., 2022), the proportion of participants exceeding the proposed cutoff values were estimated and compared to the expected values. Furthermore, the cohort was stratified by age group and methods similar to prior studies were employed to determine age‐specific cutoff values.Result: One hundred and three participants were included, comprising of 69 females (67%), with a median age of 65.4 years (interquartile range (IQR): 56.7, 70.3) and a cognitive z‐score of 0.11 (IQR: ‐0.44, 0.63). Using the reference threshold from prior studies, plasma NFL were elevated in 4 participants (3.9%, 95% confidence interval: 1.0‐9.6%) which is consistent with the expected prevalence of 5% (as 95th percentile cutoffs were used). Subsequently, we determined age‐specific plasma NFL cut‐off values for each decade through quantile regression, values ranging from 7.2 pg/mL for 40‐50 years to 58.2 pg/mL for >80 years.Conclusion: Our initial findings suggest that the previously established cutoffs for plasma NFL may be applicable in Thailand. Nonetheless, further studies with a larger and more diverse sample size may be necessary in order to fully validate the generalizability of these cutoffs and potentially establish more specific thresholds for local use.
- Open Access
- 22 December 2023
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (1) , 235-237
The case of a 26‐year‐old male with subacute progressive visual loss
- 22 December 2023
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (1) , 235-237
Open AccessThe case of a 26‐year‐old male with subacute progressive visual loss
- Open Access
- 8 March 2023
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 17 (1) , 1-5
Fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report
Background: Fluorouracil-induced leukoencephalopathy is a rare complication and has been reported to present as confusion, oculomotor abnormality, ataxia, and parkinsonism; however, there is no previous report of a presentation mimicking neuroleptic malignant syndrome. Acute cerebellar syndrome may occur, which can be explained by the extremely high accumulation of the drug in the cerebellum. However, presentation mimicking neuroleptic malignant syndrome similar to our case has never been reported. Case presentation: Here, we describe a 68-year-old Thai male presenting with advanced-stage cecal adenocarcinoma, as well as symptoms and signs indicative of neuroleptic malignant syndrome. He received two doses of intravenous metoclopramide 10 mg 6 hours before his symptoms occurred. Magnetic resonance imaging scan revealed signal hyperintensity within the bilateral white matter. Further evaluation showed that his thiamine level was extremely low. Thus, he was diagnosed with fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome. The concomitant fluorouracil-induced thiamine deficiency eventually leads to rapid depletion of thiamine and was considered a risk factor for fluorouracil-induced leukoencephalopathy. Conclusion: Fluorouracil-induced leukoencephalopathy is believed to be caused by insult causing mitochondrial dysfunction. However, the exact mechanism remains unknown, but our finding suggests that thiamine deficiency plays a crucial role in fluorouracil-induced leukoencephalopathy. Diagnosis is usually delayed due to a lack of clinical suspicion and results in significant morbidity requiring unnecessary investigations.
- 8 March 2023
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 17 (1) , 1-5
Open AccessFluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report
Background: Fluorouracil-induced leukoencephalopathy is a rare complication and has been reported to present as confusion, oculomotor abnormality, ataxia, and parkinsonism; however, there is no previous report of a presentation mimicking neuroleptic malignant syndrome. Acute cerebellar syndrome may occur, which can be explained by the extremely high accumulation of the drug in the cerebellum. However, presentation mimicking neuroleptic malignant syndrome similar to our case has never been reported. Case presentation: Here, we describe a 68-year-old Thai male presenting with advanced-stage cecal adenocarcinoma, as well as symptoms and signs indicative of neuroleptic malignant syndrome. He received two doses of intravenous metoclopramide 10 mg 6 hours before his symptoms occurred. Magnetic resonance imaging scan revealed signal hyperintensity within the bilateral white matter. Further evaluation showed that his thiamine level was extremely low. Thus, he was diagnosed with fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome. The concomitant fluorouracil-induced thiamine deficiency eventually leads to rapid depletion of thiamine and was considered a risk factor for fluorouracil-induced leukoencephalopathy. Conclusion: Fluorouracil-induced leukoencephalopathy is believed to be caused by insult causing mitochondrial dysfunction. However, the exact mechanism remains unknown, but our finding suggests that thiamine deficiency plays a crucial role in fluorouracil-induced leukoencephalopathy. Diagnosis is usually delayed due to a lack of clinical suspicion and results in significant morbidity requiring unnecessary investigations.
- Open Access
Unusual thalamic mass and subsequent gelatinous pseudocysts in an immunocompetent host: A case report